targeted therapy for biliary tract cancer胆道癌的靶向治疗.pdf

Cancers 2011, 3, 2243-2254; doi:10.3390/cancers3022243 OPEN ACCESS cancers ISSN 2072-6694 /journal/cancers Review Targeted Therapy for Biliary Tract Cancer Junji Furuse 1,* and Takuji Okusaka 2 1 Department of Internal Medicine, Medical Oncology, Kyorin University School of Medicine, 6-20-2, Shinkawa, Mitaka, Tokyo, 181-8611, Japan 2 Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan; E-Mail: tokusaka@ncc.go.jp * Author to whom correspondence should be addressed; E-Mail: jfuruse@ks.kyorin-u.ac.jp; Tel.: +81-422-47-5511; Fax: +81-422-44-0604. Received: 4 March 2011; in revised form: 10 April 2011 / Accepted: 13 April 2011 / Published: 3 May 2011 Abstract: It is necessary to establish effective chemotherapy to improve the survival of patients with biliary tract cancer, because most of these patients are unsuitable candidates for surgery, and even patients undergoing curative surgery often have recurrence. Recently, the combination of cisplatin plus gemcitabine was reported to show survival benefits over gemcitabine alone in randomized clinical trials conducted in the United Kingdom and Japan. Thus, the combination of cisplatin plus gemcitabine is now recognized as the standard therapy for unresectable biliary tract cancer. One of the next issues that need to be addressed is whether molecular targeted agents might also be effective against biliary tract cancer. Although some targ